Clinical Trial Update: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating efficacy and safety of belantamab mafodotin in combination with bortezomib and dexamethasone versus daratumumab with bortezomib and dex…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Blenrep (belantamab mafodotin)
• DARZALEX (daratumumab)
• Decadron (Dexamethasone)
• Velcade (bortezomib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Multiple Myeloma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-10-24